Kangstem Biotech Obtains European Patent for Stem Cell-Based Osteoarthritis Treatment
[Asia Economy Reporter Lee Jung-yoon] Kangstem Biotech announced on the 22nd that it has obtained a patent related to a cartilage differentiation-promoting complex containing acellular cartilage fragments and stem cells, as well as its uses.
The company stated, "The present invention relates to a cartilage differentiation-promoting complex containing acellular cartilage fragments and stem cells, and its uses," adding, "It concerns a pharmaceutical composition for preventing or treating joint diseases containing stem cells or their culture and acellular cartilage fragments, and a method for preventing or treating joint diseases using the composition."
Hot Picks Today
"Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Don't Throw Away Coffee Grounds" Transformed into 'High-Grade Fuel' in Just 90 Seconds [Reading Science]
- Signed Without Viewing for 1.6 Billion Won... Jamsil and Seongbuk Jeonse Prices Jump 200 Million Won in a Month [Real Estate AtoZ]
- "Groups of 5 or More Now Restricted"... Unrelenting Running Craze Leaves Citizens and Police Exhausted
- "Even With a 90 Million Won Salary and Bonuses, It Doesn’t Feel Like Much"... A Latecomer Rookie Who Beat 70 to 1 Odds [Scientists Are Disappearing] ③
They further explained, "It can be widely used for the treatment of joint diseases such as degenerative osteoarthritis, multiple arthritis accompanied by cartilage damage, hip arthritis, knee arthritis, or spinal arthritis."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
